Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

15 Aug 2005 07:01

Torex Retail PLC15 August 2005 Torex Retail Plc15 August 2005 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR ANKER PLC Offer Unconditional as to Acceptances As at 3.00 p.m. on 12 August 2005, valid acceptances had been received inrespect of 40,810,140 Anker Shares (representing approximately 98.14 per cent ofAnker's issued share capital). Accordingly, the Board of Torex Retail Plc("Torex Retail") announces that the offer (the "Offer") made by UBS InvestmentBank on behalf of Torex Retail for Anker Plc ("Anker") has been declaredunconditional as to acceptances. Prior to the posting of the Offer Document, Torex Retail had receivedirrevocable undertakings or letters of intent from the Anker Directors andcertain other Anker Shareholders to accept or procure the acceptance of theOffer in respect of, in aggregate, 31,347,988 Anker Shares, representingapproximately 75.4 per cent. of the existing issued ordinary share capital ofAnker. Included in the valid acceptances of the Offer set out above areacceptances in respect of 31,347,988 Anker Shares, representing approximately75.4 per cent. of the existing issued ordinary share capital of Anker, receivedpursuant to such irrevocable undertakings and letter of intent. The Offer remains conditional upon the admission to trading on AIM of the NewTorex Retail Shares issued as consideration under the Offer becoming effective. Therefore, following the allocations made pursuant to the Mix and Matchfacility, application has been made for the admission of 55,297,740 New TorexRetail Shares to trading on AIM and it is expected that these New Torex RetailShares will be admitted to trading on AIM and that dealings in those shares willcommence on 18 August 2005, when it is also expected that the Offer will becomewholly unconditional. The board of Torex Retail announces that the Mix and Match Facility has now beenclosed with effect from 3.00 p.m. on 12 August 2005. Those Anker Shareholdersthat elected to receive additional cash under the Mix and Match Facility willreceive in total 94.2 pence in cash and 1.193 New Torex Retail Shares for everyAnker share held. Elections to receive additional New Torex Retail Shares underthe Mix and Match Facility will be received in full. The Offer will remain open for acceptance until further notice, although the Mixand Match Facility is no longer available. For Anker Shares held in certificated form, Forms of Acceptance should becompleted, signed and returned in accordance with instructions set out in theOffer Document and in the Form of Acceptance, so as to be received as soon aspossible. For Anker Shares held in uncertificated form, an ElectronicAcceptance should be made in accordance with instructions set out in the OfferDocument so that the TTE Instruction settles as soon as possible. Save as disclosed in this announcement, neither Torex Retail nor any personsdeemed to be acting in concert with it for the purposes of the Offer owned anyAnker Shares (or rights over such shares) on 29 June 2005 (being the lastdealing day prior to the commencement of the Offer period) nor has Torex Retailnor any person deemed to be acting in concert with it for the purposes of theOffer acquired or agreed to acquire any Anker Shares (or rights over suchshares) during the Offer period other than by way of acceptances of the Offer. The Offer will remain open until further notice. At least 14 days' notice willbe given before the Offer is closed. Terms defined in the formal offer document dated 22 July 2005 (the "OfferDocument") shall, unless the context requires otherwise, have the same meaningsin this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn UBS Investment Bank Telephone: 020 7567 8000Ben Robertson/Jackie Lee This announcement is issued by UBS Investment Bank which is authorised andregulated in the United Kingdom by the Financial Services Authority. UBSInvestment Bank is acting exclusively for Torex Retail and is acting for no oneelse in connection with the Offer and will not be responsible to anyone otherthan Torex Retail for providing the protections afforded to customers of UBSInvestment Bank nor for providing advice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jul 20138:45 amRNSTissue Regenix Key Appointment at USA Subsidiary
25th Jul 20134:59 pmRNSHolding(s) in Company
17th Jul 20137:00 amRNSAppointment of Non-Executive Director
10th Jul 20137:00 amRNSAppointment of Non-Executive Director
18th Jun 20137:00 amRNSTissue Regenix advances US commercialisation
14th Jun 201312:43 pmRNSResult of AGM
14th Jun 20137:00 amRNSPresentation of dCELL at heart valve event
28th May 20137:00 amRNSAppointment of Business Development Manager
14th May 20133:47 pmRNSAnnual Report and Notice of AGM
13th May 20137:00 amRNSPreliminary results for the year ended 31 Jan 2013
3rd May 20137:00 amRNSNotice of Results
2nd May 20137:00 amRNSResults of dCELL Dermis trial
29th Apr 20137:00 amRNSChange of Nominated Adviser and Broker
16th Apr 20137:00 amRNSApproval for start of clinical research trial
2nd Apr 20137:00 amRNSTissue Regenix makes appointment to US subsidiary
11th Mar 20137:00 amRNSDirector Change
15th Feb 20132:38 pmRNSHolding(s) in Company
14th Feb 20137:00 amRNSSuccessful safety study of dCELL® Meniscus
11th Feb 20132:57 pmRNSDirectorate Change
9th Jan 20137:15 amRNSHolding(s) in Company
30th Nov 201211:21 amRNSTissue Regenix board changes
26th Nov 20127:00 amRNSSets up US subsidiary
19th Nov 20127:00 amRNSAdds new patent global licence portfolio
4th Oct 20127:00 amRNSInterim data from clinical trial of dCELL® Dermis
4th Oct 20127:00 amRNSHalf Yearly Report
1st Oct 201210:57 amRNSTissue Regenix - senior development appointment
28th Sep 20123:30 pmRNSNotice of Results
7th Sep 20127:00 amRNSdCELL(R) vascular patch is safe and effective
2nd Aug 20122:31 pmRNSTissue Regenix makes appointment to Cardiac team
31st Jul 20123:02 pmRNSDirector/PDMR Shareholding
19th Jun 20122:39 pmRNSHolding(s) in Company
14th Jun 20127:00 amRNSResearch Update
11th Jun 201212:35 pmRNSResult of AGM
25th May 20127:00 amRNSExpands scope of development activities with NHSBT
10th May 20127:00 amRNSFinal Results
19th Apr 20121:49 pmRNSPoster shown at SAWC
16th Apr 20123:18 pmRNSNotice of Results
7th Feb 20124:00 pmRNSIssue of Equity and Total Voting Rights
11th Jan 201211:36 amRNSHolding(s) in Company
6th Jan 20125:05 pmRNSHolding(s) in Company
3rd Jan 20125:45 pmRNSHolding(s) in Company
3rd Jan 20125:43 pmRNSHolding(s) in Company
3rd Jan 20128:49 amRNSHolding(s) in Company
28th Dec 201112:00 pmRNSResult of General Meeting
8th Dec 201112:53 pmRNSIssue of Equity
25th Nov 20112:23 pmRNSUniversity Partner wins Queen's Anniversary Prize
4th Nov 20112:16 pmRNSHolding(s) in Company
14th Oct 20112:33 pmRNSHolding(s) in Company
10th Oct 20117:00 amRNSHalf Yearly Report
26th Jul 201111:04 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.